Nortriptyline Shortage: What Providers and Prescribers Need to Know in 2026

Nortriptyline — a secondary amine tricyclic antidepressant (TCA) approved for depression and frequently used off-label for neuropathic pain, migraine prophylaxis, and smoking cessation — is not currently in a national shortage. As of 2026, it remains off the FDA Drug Shortage Database and the ASHP active shortage list.

That said, providers should understand the current supply landscape, patient-level access challenges, and the clinical considerations that affect nortriptyline prescribing — including pharmacogenomics and dose adjustment. This guide covers everything prescribers need to know.

Supply Status: What the Data Shows in 2026

Nortriptyline is a multi-manufacturer generic available in four capsule strengths (10 mg, 25 mg, 50 mg, 75 mg) and an oral solution (10 mg/5 mL). The overall drug shortage environment has improved: according to ASHP, new drug shortage reports in 2025 reached their lowest level in nearly 20 years.

Nortriptyline's risk profile for shortage is low due to: (1) off-patent status since the 1970s, (2) multiple active manufacturers including Teva, Sun Pharmaceutical, and others, (3) relatively lower prescription volume compared to SSRIs, reducing demand-driven supply stress, and (4) Tier 1 formulary placement on virtually all commercial, Medicare, and Medicaid plans.

However, providers should be aware that localized stock gaps occur at the pharmacy level despite national supply stability. The oral solution formulation has notably limited stocking in community pharmacies.

Clinical Profile: Key Prescribing Considerations

Nortriptyline's clinical profile makes it a useful tool in specific patient populations, with advantages over other TCAs including reduced anticholinergic burden and better tolerability than its parent compound amitriptyline.

FDA-approved indication: Depression in adults only. Not approved for pediatric use.

Common off-label uses: Neuropathic pain, diabetic peripheral neuropathy, postherpetic neuralgia, myofascial pain, migraine prophylaxis, smoking cessation, ADHD.

Dosing range: For depression: 75-150 mg/day (max 150 mg/day with TDM; some sources allow up to 200 mg in hospitalized patients). For pain: typically 10-75 mg/day at bedtime. Start low (10-25 mg) and titrate.

Therapeutic drug monitoring: Optimal plasma levels for antidepressant effect: 50-150 ng/mL. Monitoring recommended when doses exceed 100 mg/day. Essential in CYP2D6 poor metabolizers.

Cardiac monitoring: Obtain baseline ECG in older adults and patients with cardiac disease. Monitor for QTc prolongation. Contraindicated immediately post-MI.

Pharmacogenomics: CYP2D6 and Clinical Implications

Nortriptyline is primarily metabolized by CYP2D6. This has significant clinical implications that providers should discuss with patients and consider testing for when available:

Poor metabolizers (~7-10% of Caucasians): Elevated nortriptyline levels, increased anticholinergic and CNS adverse effects. CPIC recommends avoiding nortriptyline or using significantly reduced doses with TDM.

Ultrarapid metabolizers: Subtherapeutic levels, reduced efficacy. CPIC recommends avoiding nortriptyline and selecting an alternative antidepressant.

CYP2D6 drug interactions: Adjust dose whenever a CYP2D6 inhibitor (e.g., fluoxetine, paroxetine, bupropion, terbinafine, quinidine) is added or removed from the regimen.

High-Risk Drug Interactions to Monitor

MAOIs (contraindicated): Risk of hyperpyretic crisis, convulsions, and death. Require at least 14-day washout from MAOI to nortriptyline; at least 5 weeks after fluoxetine.

Serotonergic agents: Risk of serotonin syndrome with SSRIs, SNRIs, tramadol, triptans, linezolid, IV methylene blue.

QTc-prolonging agents: Additive risk with amiodarone, quinidine, procainamide, macrolide antibiotics, antipsychotics. Review QTc at baseline and after combination.

Anticholinergics: Additive anticholinergic burden; risk of urinary retention, paralytic ileus, cognitive impairment (especially in elderly).

When Patients Can't Find Nortriptyline: Guidance for Prescribers

When patients report difficulty filling nortriptyline, consider these steps:

Recommend checking independent pharmacies or warehouse club pharmacies (Costco, Sam's Club) which often source from different distributors than chain pharmacies.

Consider adjusting the dose strength prescription — for example, two 25 mg capsules instead of one 50 mg capsule — if a specific strength is temporarily unavailable.

For long-term patients, consider switching to 90-day mail-order fills, which are less susceptible to localized stock gaps.

Refer patients to medfinder.com/providers — a service that calls nearby pharmacies to locate medications, including nortriptyline.

Therapeutic Alternatives When Nortriptyline Is Unavailable

In true access situations, consider the following alternatives depending on the indication:

Depression (TCA class): Amitriptyline (tertiary amine; expect more sedation) or desipramine (secondary amine; similar profile to nortriptyline)

Neuropathic pain: Amitriptyline (more evidence for neuropathic pain than nortriptyline), duloxetine (FDA-approved for diabetic neuropathy), gabapentin, or pregabalin

Depression (non-TCA): SSRIs (sertraline, escitalopram) or SNRIs (duloxetine, venlafaxine) for patients where the primary indication is depression

For more tools to help your patients access their medications, visit medfinder.com/providers.